When a state Medicaid programme starts paying for GLP-1 drugs labeled for obesity, the bill for those drugs goes up. A study in JAMA Health Forum suggests the net increase is smaller than that figure implies, because some of the new obesity-labeled prescriptions appear to replace diabetes-labeled versions of the same molecules, which every state … Read more
A systematic review has pulled together 26 economic evaluations of the approved weight-loss drugs, and the pattern it reports is worth knowing before anyone quotes “cost-effective” at you. Semaglutide came out ahead of liraglutide consistently enough that the authors call liraglutide generally not cost-effective. Tirzepatide bought the most health of any drug reviewed, and frequently … Read more
The self-pay price of the 4 mg Wegovy tablet rises from $149 to $199 a month on 1 September 2026. This is not a leak or a forecast: Novo Nordisk published the end date when it launched the offer, and the footnote was still on NovoCare’s own pricing page when we read it on 31 … Read more
Eli Lilly announced on 26 August 2026 that a real-world analysis of adults over 55 found lower healthcare costs among people who stayed on Zepbound (tirzepatide) than among matched untreated adults, and framed the result against the $195 monthly net price under Medicare’s GLP-1 Bridge programme. The underlying paper is peer-reviewed and published in Diabetes, … Read more
Novo Nordisk announced in February that from 1 January 2027 it will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 a month — a reduction of roughly 50% for Wegovy and 35% for Ozempic. It is a genuinely large number and it made a lot of headlines. For most people reading … Read more